Proficio Capital Partners LLC Acquires 1,562 Shares of Eli Lilly and Company (NYSE:LLY)
Proficio Capital Partners LLC lifted its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 30.2% in the fourth ...
Unpacking the Latest Options Trading Trends in Eli Lilly
Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli ...
Eli Lilly and Company (NYSE:LLY) Given Average Rating of “Moderate Buy” by Brokerages
Shares of Eli Lilly and Company (NYSE:LLY – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the ...
Zacks Investment Research on MSN6d
Eli Lilly Rises 7.5% YTD: Time to Buy, Sell or Hold the Stock?
Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...
Healio3d
GLP-1 drugs may extend life, graft survival for kidney transplant recipients with diabetes
For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with ...
pharmaphorum4d
Lilly to invest $2.5bn for obesity, diabetes drug production
Eli Lilly has followed Novo Nordisk in announcing ... supporting products like GLP-1 agonist Trulicity (dulaglutide) and dual GIP/GLP-1 agonist Mounjaro (tirzepatide) for diabetes, as well as ...
pharmaphorum3d
EMA finds no evidence GLP-1 agonists cause thyroid cancer
The EMA’s safety committee has said that, after a review of available data, it has found no evidence that GLP-1 agonist drugs such as Novo Nordisk’s Ozempic and Eli Lilly’s Trulicity can ...